|Bid||4,110.00 x 51000|
|Ask||4,260.00 x 53800|
|Day's range||4,155.50 - 4,255.00|
|52-week range||4,025.00 - 5,377.00|
|PE ratio (TTM)||130.45|
|Dividend & yield||0.26 (0.49%)|
|1y target est||N/A|
The chief executive of Shire has questioned investors' valuation of his company, arguing the potential of a number of promising drugs has yet to be factored into its share price. Flemming Ornskov also ...
The Zacks Analyst Blog Highlights: Merck, Eli Lilly, Celgene, Gilead Sciences and Shire
A breakthrough cancer therapy that can wipe out leukemia in some deathly ill children and young adults comes with an expensive, long-lasting side effect.